Literature DB >> 193072

Estrogens and endometrial carcinoma.

L A Gray, W M Christopherson, R N Hoover.   

Abstract

A group of 205 women with endometrial carcinoma was matched for age, parity, and year of operation with a group of 205 women who had had hysterectomies for benign disease. In the former group, 32 patients had used conjugated estrogens, while in the latter group 12 had used this hormone, yielding a relative risk of 3.1 (P = 0.0008). Users of other forms of systemic estrogens showed similar elevations in relative risk. Relative risk was related to duration of use, progressing from no evidence of risk among those using the hormone for less than 5 years to an 11.5-fold greater risk for those using it for 10 years or more. Risk was also related to the strength of the medication. The relative risk for users of the 1.25-mg tablets was 12.7 as compared to a two- to fourfold greater risk among users of lesser strength tablets.

Entities:  

Keywords:  Age Factors; Biology; Cancer; Comparative Studies; Contraception; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Estrogen--therapeutic use; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--side effects; Contraceptive Agents, Female--therapeutic use; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Contraceptive Agents--therapeutic use; Demographic Factors; Diseases; Endocrine System; Endometrial Cancer; Estrogens--administraction and dosage; Estrogens--side effects; Estrogens--therapeutic use; Family Planning; Hormones; Hysterectomy; Longterm Effects; Menopause; Neoplasms; Parity; Physiology; Population; Population Dynamics; Research Methodology; Studies; Time Factors; Uterine Effects

Mesh:

Substances:

Year:  1977        PMID: 193072

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  13 in total

Review 1.  Hormonal replacement therapy.

Authors:  Regine Sitruk-Ware
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  Hormone replacement therapy and breast cancer, endometrial cancer and cardiovascular disease: risks and benefits.

Authors:  M K Goddard
Journal:  Br J Gen Pract       Date:  1992-03       Impact factor: 5.386

Review 3.  [The role of progestins].

Authors:  H I Wyss
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

4.  Oestrogen therapy and endometrial cancer.

Authors: 
Journal:  Br Med J       Date:  1977-07-23

Review 5.  Postmenopausal hormone replacement: are two hormones better than one?

Authors:  H Wood; R Wang-Cheng; A B Nattinger
Journal:  J Gen Intern Med       Date:  1993-08       Impact factor: 5.128

6.  The decreasing incidence of endometrial cancer: public health implications.

Authors:  D F Austin; K M Roe
Journal:  Am J Public Health       Date:  1982-01       Impact factor: 9.308

7.  The menopause.

Authors:  P F Brenner
Journal:  West J Med       Date:  1982-03

8.  The epidemic of endometrial cancer: a commentary.

Authors:  H Jick; A M Walker; K J Rothman
Journal:  Am J Public Health       Date:  1980-03       Impact factor: 9.308

9.  Prescribing estrogen during menopause: physician survey of practices in 1974 and 1981.

Authors:  B H Pasley; S J Standfast; S H Katz
Journal:  Public Health Rep       Date:  1984 Jul-Aug       Impact factor: 2.792

10.  Comparison of serum oestrogen concentrations in post-menopausal women taking oestrone sulphate and oestradiol.

Authors:  A B Anderson; E Sklovsky; L Sayers; P A Steele; A C Turnbull
Journal:  Br Med J       Date:  1978-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.